Authors

Hua Su#, Jiaen Wu, Tao Li

Departments

Hezhou People's Hospital of China, Hezhou, PR China

Abstract

patients with arrhythmia. 

Methods: A total of 116 patients with arrhythmia who were treated in our hospital from April 2017 to June 2019 were divided into the control group (n-60) and experimental group (n-56) according to different treatment methods. The control group was treated with bisoprolol. The initial dosage was 1.25-2.5 mg/d. The dosage was doubled 14 days later until the maximum tolerable dose (5-10 mg/d) was achieved. The experimental group was treated with amiodarone on the basis of the control group. The initial amiodarone was 200 mg three times a day for seven days, followed by 200 mg two times a day for seven days and then 200 mg one time a day, thereby gradually decreasing maintenance treatment. The clinical efficacy, adverse reactions and cardiac function indicators in the control and experimental groups [left ventricular ejection fraction (LVEF), left ventricular diastolic diameter (LLVEDD) and left ventricular posterior wall thickness (LVPWD)], haemodynamic parameters (plasma concentration, erythrocyte sedimentation rate, haematocrit and fibrinogen) and inflammatory factors [hypersensitive C-reactive protein (hs-CRP) and serum brain natriuretic peptide (BNP)] levels were compared between the control and experimental groups. 

Results: The total effective rate was 89.29% in the experimental group and 73.33% in the control group, and there was a significant difference in the total effective rate between the two groups (P<0.05). Before treatment, there was no significant difference in the levels of LVEF, LVEDD and LVPWD between the control and experimental groups (P>0.05); after treatment, the levels of LVEDD and LVPWD in the control and experimental groups were significantly lower than those before treatment, and the levels of LVEF were significantly higher than those before treatment (P<0.05). Prior to treatment, there was no significant difference in haemodynamic parameters between the two groups (P>0.05). After treatment, the levels of fibrinogen, erythrocyte sedimentation rate, haematocrit and plasma viscosity in the two groups were significantly lower than those before treatment, and the levels of fibrinogen, erythrocyte sedimentation rate, haematocrit and plasma viscosity in the experimental group were significantly lower than those in the control group (P<0.05). Prior to treatment, there was no significant difference in the levels of hs-CRP and BNP between the two groups (P>0.05); after treatment, the levels of hs-CRP and BNP in the two groups were lower than those before treatment, and the levels of hs-CRP and BNP in the experimental group were significantly lower than those in the control group (P<0.05). Moreover, the patients had better tolerance to amiodarone, and no thyroid dysfunction occurred after treatment. Further, there was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Over the course of treatment, there were mild adverse reactions, such as blood pressure drop, nausea, vomiting and dizziness in both groups. 

Conclusion: Bisoprolol combined with amiodarone can effectively relieve clinical symptoms, reduce adverse reactions, improve haemodynamics, inhibit inflammation and reduce the variability of arrhythmia in patients with arrhythmia while featuring high safety and obvious effects.

Keywords

Objective: To analyse the effects of bisoprolol combined with amiodarone on cardiac function, haemodynamics and inflammatory factors in patients with arrhythmia. Methods: A total of 116 patients with arrhythmia who were treated in our hospital from April 2017 to June 2019 were divided into the control group (n-60) and experimental group (n-56) according to different treatment methods. The control group was treated with bisoprolol. The initial dosage was 1.25-2.5 mg/d. The dosage was doubled 14 days later until the maximum tolerable dose (5-10 mg/d) was achieved. The experimental group was treated with amiodarone on the basis of the control group. The initial amiodarone was 200 mg three times a day for seven days, followed by 200 mg two times a day for seven days and then 200 mg one time a day, thereby gradually decreasing maintenance treatment. The clinical efficacy, adverse reactions and cardiac function indicators in the control and experimental groups [left ventricular ejection fraction (LVEF), left ventricular diastolic diameter (LLVEDD) and left ventricular posterior wall thickness (LVPWD)], haemodynamic parameters (plasma concentration, erythrocyte sedimentation rate, haematocrit and fibrinogen) and inflammatory factors [hypersensitive C-reactive protein (hs-CRP) and serum brain natriuretic peptide (BNP)] levels were compared between the control and experimental groups. Results: The total effective rate was 89.29% in the experimental group and 73.33% in the control group, and there was a significant difference in the total effective rate between the two groups (P<0.05). Before treatment, there was no significant difference in the levels of LVEF, LVEDD and LVPWD between the control and experimental groups (P>0.05); after treatment, the levels of LVEDD and LVPWD in the control and experimental groups were significantly lower than those before treatment, and the levels of LVEF were significantly higher than those before treatment (P<0.05). Prior to treatment, there was no significant difference in haemodynamic parameters between the two groups (P>0.05). After treatment, the levels of fibrinogen, erythrocyte sedimentation rate, haematocrit and plasma viscosity in the two groups were significantly lower than those before treatment, and the levels of fibrinogen, erythrocyte sedimentation rate, haematocrit and plasma viscosity in the experimental group were significantly lower than those in the control group (P<0.05). Prior to treatment, there was no significant difference in the levels of hs-CRP and BNP between the two groups (P>0.05); after treatment, the levels of hs-CRP and BNP in the two groups were lower than those before treatment, and the levels of hs-CRP and BNP in the experimental group were significantly lower than those in the control group (P<0.05). Moreover, the patients had better tolerance to amiodarone, and no thyroid dysfunction occurred after treatment. Further, there was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Over the course of treatment, there were mild adverse reactions, such as blood pressure drop, nausea, vomiting and dizziness in both groups. Conclusion: Bisoprolol combined with amiodarone can effectively relieve clinical symptoms, reduce adverse reactions, improve haemodynamics, inhibit inflammation and reduce the variability of arrhythmia in patients with arrhythmia while featuring high safety and obvious effects.

DOI:

10.19193/0393-6384_2020_3_204